Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Ivonescimab (SMT112) in 1L Non-small cell lung carcinoma. The expected timing is based on the latest available company guidance and may change.
HARMONi-3 trial. 12/5/22- Trial collab w/ Akeso. 05/09/23- Dosed 1st patient. Q2'25- Enrollment ongoing. 10/19/25- Squamous PFS readout in H2 2026 & non-squamous PFS readout in H1 2027. 08/05/26:- HARMONi-3 Ph3 evaluates ivonescimab plus chemo vs pembrolizumab plus chemo, with separate squamous and non-squamous cohorts.
Verification
Confirm timing and program details against the company announcement or filing.